INTRODUCTION
============

In eukaryotic cells, most proteins destined for membrane insertion or secretion are first processed in the endoplasmic reticulum (ER). Nascent polypeptide chains, synthesized by cytoplasmic ribosomes, enter the ER lumen at specialized sites in the ER membrane called translocons, which are complexes of several ER membrane proteins that associate to form a pore ([@b68-0060135]). Sec61α, Sec61β and Sec61γ form the pore, and this trimeric complex is associated with other proteins including ERj1, Sec62 and Sec63 in mammals ([@b44-0060135]; [@b94-0060135]). Mutations in *SEC63* cause polycystic liver disease (PCLD) in humans, a progressive disorder characterized by the presence of many (\>20) cysts throughout the liver ([@b11-0060135]; [@b19-0060135]). PCLD often co-occurs in patients with autosomal dominant polycystic kidney disease (PCKD), but can also exist as a separate disease without kidney cysts ([@b79-0060135]). Polycystic livers can grow up to ten times their normal size, resulting in significant patient morbidity. Although a few therapeutic interventions are available to slow cyst growth, only liver transplantation can change the course of the disease ([@b18-0060135]). It remains unclear how mutations in *SEC63* cause liver cysts, but possibilities include disrupted trafficking of vital proteins such as polycystin-1, an integral cilia membrane protein mutated in PCKD ([@b20-0060135]) and disrupted tethering of proteins to the cytosolic face of the ER ([@b48-0060135]). Another possibility is that disruption of *SEC63* triggers ER stress that contributes to the pathophysiology of PCLD.

Nascent polypeptides are transported across the ER translocon for processing, folding and maturation ([@b61-0060135]). An imbalance between the load of unfolded preproteins that enter the ER and the capacity of this organelle to properly process the load results in ER 'stress': in this case an accumulation of misfolded proteins in the ER lumen ([@b64-0060135]). This activates the unfolded protein response (UPR), a conserved cellular homeostatic mechanism, in an attempt to reconcile the imbalance. If the imbalance persists, the UPR can ultimately lead to cell death ([@b64-0060135]). Not surprisingly, elevation of ER stress and activation of the UPR are implicated in the pathology of many diseases, including myelin disorders such as multiple sclerosis and Charcot-Marie-Tooth disease ([@b10-0060135]; [@b37-0060135]).

Myelin is a multilayered membrane formed by the wrapping of glial cells around axons that allows for efficient conduction of action potentials in the vertebrate nervous system ([@b50-0060135]). Specialized glial cells generate the myelin sheath: oligodendrocytes in the central nervous system (CNS) and Schwann cells in the peripheral nervous system (PNS). Myelin is formed as an elaboration of the plasma membrane of the glial cells, which must generate tremendous amounts of membrane proteins and lipids ([@b1-0060135]). Segments of myelin are separated by the nodes of Ranvier, which are unmyelinated regions of axonal membrane containing a high density of voltage-gated sodium channels (NaV) ([@b66-0060135]; [@b67-0060135]). These channels propagate the action potential by generating current in response to membrane depolarization ([@b62-0060135]).

###### TRANSLATIONAL IMPACT

**Clinical issue**

Mutations in human *SEC63* cause polycystic liver disease (PCLD). There are few treatment options for PCLD; only invasive surgery or liver transplantation can change the course of the disease. Although it is known that SEC63 is part of the endoplasmic reticulum (ER) translocon complex, which transports nascent polypeptides across membranes for folding and maturation in the ER, how mutations in *SEC63* cause PCLD has been unclear. Among many hypotheses, it has been proposed that *SEC63* mutations might trigger ER stress, which occurs when the capacity of the ER to process nascent or damaged proteins is overloaded. Many studies have linked ER stress with myelin disorders, including multiple sclerosis and peripheral neuropathy.

**Results**

In a forward genetic screen for zebrafish mutants with abnormal sodium channel clustering in myelinated axons, the authors identified *sec63^st67^*, a missense mutation in *sec63*. Mutant larvae showed multiple defects in myelinated axons in the peripheral nervous system (PNS) and central nervous system (CNS), including disruptions in myelination. Additionally, liver development was abnormal in the *sec6*3*^st67^* mutants; however, cysts were not observed in the liver or kidneys. Swelling and fragmentation of the ER was observed in cells of the PNS, CNS and liver, and multiple molecular markers of ER stress were activated in *sec63^st67^* mutants.

**Implications and future directions**

These findings introduce the *sec63^st67^* mutant as a new model for studying the function of a gene implicated in PCLD, as well as the role of ER stress in disorders of disrupted myelination. Given that myelinating glia and hepatocytes synthesize large amounts of membrane and secreted proteins during development, they are highly susceptible to disruptions in the translocon machinery. This report advances our understanding of how ER stress contributes to disease processes and provides a new model for investigating the underlying mechanisms.

To discover genes required for the development and organization of myelinated axons, we performed a genetic screen in zebrafish to identify mutants with disruptions in the node of Ranvier ([@b83-0060135]; [@b84-0060135]) (M.G.V. and W.S.T., unpublished data). One mutation identified in this screen disrupts the zebrafish ortholog of the translocon protein Sec63. We show that the UPR is active in zebrafish *sec63* mutants and that *sec63* mutant axons in the CNS and the PNS are hypomyelinated, with reduced and abnormal NaV clusters. Given the role of Sec63 in human PCLD, we also examined the livers of zebrafish *sec63* mutants. We show that pathology develops in this organ, with unusual accumulations of enlarged ER cisternae, disrupted bile canaliculi and accumulation of large, debris-laden lysosomes. These results raise the possibility that ER stress contributes to PCLD caused by *SEC63* mutations and offer a new model for diseases involving protein trafficking and ER stress.

RESULTS
=======

Identification and analysis of *st67* mutants
---------------------------------------------

In order to understand the genetic mechanisms underlying the organization of myelinated axons, we performed a genetic screen in zebrafish to identify mutations that affect the development of the nodes of Ranvier ([@b83-0060135]; [@b84-0060135]) (M.G.V. and W.S.T., unpublished data). In this screen, we examined expression of NaV along zebrafish axons in whole-mounts of immunostained larvae. A mutation, *st67*, was identified with a strong defect in NaV clustering along axons. *st67* mutants have morphologically abnormal and reduced numbers of NaV channel clusters along the posterior lateral line nerve (PLLn) at 5 days post-fertilization (dpf) ([Fig. 1D,E](#f1-0060135){ref-type="fig"}). Time-course analysis determined that the number of nodal NaV clusters in the mutant PLLn was normal at 3 dpf ([Fig. 1A,B,E](#f1-0060135){ref-type="fig"}) but was significantly reduced in mutant larvae at 4 dpf and later ([Fig. 1E](#f1-0060135){ref-type="fig"}). In *st67* mutants, axonal acetylated tubulin expression in the PLLn appeared to be normal ([Fig. 1B,D](#f1-0060135){ref-type="fig"}) and the number of Schwann cells along the PLLN at 40 hours post-fertilization (hpf) was also similar to that in the wild type, as determined by in situ hybridization for *sox10* (data not shown). The *sec63^st67^* mutation is lethal; mutant larvae fail to inflate their swim bladders ([supplementary material Fig. S1](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009217/-/DC1)) and most do not survive past 14 dpf.

![**Nodes of Ranvier are abnormal in *st67* mutant zebrafish at 5 dpf.** (A--D) Images of axons from the posterior lateral line nerve (PLLn) in larvae of the indicated genotypes at 3 (A,B) and 5 dpf (C,D). Axons were double-labeled with antibodies against acetylated tubulin (AcTub, red) and NaV (green). NaV labeling is shown alone in A′--D′. In wild-type and *st67* mutant larvae, NaV clusters (arrowheads) appear as discrete labeled puncta. At 3 dpf, no differences are observed in either frequency or morphology of NaV clusters in *st67* mutants compared with wild type (A,B). At 5 dpf, *st67* mutants have fewer NaV clusters and many NaV clusters are more diffuse than in wild-type PLLn (C,D). (E) Quantification of the total number of NaV clusters along the entire length of the PLLn in wild-type and *st67*/+ larvae (WT, black bars) compared with homozygous *st67* mutants (*st67*, gray bars) at the indicated developmental stages. *P* values for unpaired *t*-test comparisons (two-tailed) are shown; error bars indicate s.d. Sample sizes: at 3 dpf, 23 siblings (WT and *st67/+*) and 9 mutants; at 4 dpf, 18 siblings and 8 mutants; at 5 dpf, 7 siblings and 9 mutants. Genotypes were assessed by PCR after photography. Scale bars: 10 μm (A--D).](DMM009217F1){#f1-0060135}

To better understand myelination defects in the *st67* mutants, we examined nerve ultrastructure by transmission electron microscopy (TEM). In the developing PNS of mammals and zebrafish, Schwann cells sort axonal segments away from other axons and subsequently myelinate them ([@b88-0060135]; [@b60-0060135]). At 3 dpf, an early stage of myelination, the extent of axon sorting and myelination by Schwann cells was similar in *st67* mutant PLLn and in wild-type PLLn ([Fig. 2F,G](#f2-0060135){ref-type="fig"}). By contrast, at 5 dpf, fewer axons were sorted and myelinated in the *st67* mutant PLLn compared with wild type ([Fig. 2A--D,F,G](#f2-0060135){ref-type="fig"}), and those axons that were myelinated in *st67* mutants were surrounded by fewer myelin wraps compared with wild type (wild type, 6.17±0.98 wraps, *n*=6 axons from four siblings; *st67* mutant, 4.5±0.55 wraps, *n*=6 axons from three mutants; *P*=0.001). In *st67* mutants, Schwann cells had abnormally swollen ER ([Fig. 2D,E](#f2-0060135){ref-type="fig"}), which is indicative of ER stress and ER lumenal protein accumulation ([@b80-0060135]; [@b70-0060135]). Thus, the initial stages of myelination and node of Ranvier formation appear normal in *st67* mutants at 3 dpf, but myelination and nodal NaV clusters are disrupted by 5 dpf.

![**PLLn axons are hypomyelinated in *st67* mutants.** (A--E) TEM images showing cross-section through the PLLn at 5 dpf. Sorted axons(s) are completely surrounded by Schwann cells and some sorted axons are myelinated (\*). In the wild type (A,C), many axons are surrounded by several wraps of myelin at 5 dpf. In *st67* mutants (B,D), fewer axons are myelinated at 5 dpf, and irregular Schwann cell cytoplasm is observed with visibly swollen endoplasmic reticulum (D). (E) Blow-up of boxed region in D showing swollen ER (arrows). (F,G) A significant decrease in both sorted (F) and myelinated (G) axons was detected in *st67* mutant larvae at 5 dpf, but not at 3 dpf. The *P* values for unpaired *t*-test comparisons (two-tailed) are shown; error bars indicate s.d. Sample sizes: at 3 dpf, 4 nerves from 4 siblings and 6 nerves from 5 mutants; at 5 dpf, 8 nerves from 5 siblings and 6 nerves from 3 mutants. All larvae were imaged at and quantifications made from approximately the same location along the anterioposterior axis, at the level of the 7th hemisegment. Scale bars: 2 μm (A,B); 0.5 μm (C,D).](DMM009217F2){#f2-0060135}

Ultrastructural analysis revealed that the nodes of Ranvier are similar in wild-type and *st67* mutants at 5 dpf ([supplementary material Fig. S2](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009217/-/DC1)). One notable difference, however, between mutant and wild-type siblings was that Schwann cell nuclei were often directly over or in close proximity to nodes of Ranvier in *st67* mutants ([supplementary material Fig. S2](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009217/-/DC1); 4 of 8 mutant nodes examined and 0 of 12 wild-type nodes). Schwann cell nuclei are normally located roughly in the middle of a myelin segment ([@b42-0060135]), but have been observed over nodes in mammalian models of peripheral neuropathy ([@b41-0060135]; [@b63-0060135]).

Examination of NaV expression and myelin in the CNS of *st67* mutants revealed that the spinal cord was more severely affected than the PLLn. In contrast to the PLLn, which is indistinguishable from the wild type at 3 dpf, there were fewer NaV clusters in the ventral spinal cord of the mutant at 3 dpf ([Fig. 3A,B](#f3-0060135){ref-type="fig"}; [Fig. 4B--F](#f4-0060135){ref-type="fig"}). We did not observe a reduction in oligodendrocyte number in the spinal cord at 40 hpf using in situ hybridization for *sox10* (data not shown). TEM analysis at 5 dpf showed that axons in the spinal cord were more thinly myelinated in the *st67* mutant than in the wild type ([Fig. 3C,D](#f3-0060135){ref-type="fig"}; wild type, 3.16±0.85 wraps, *n*=25 axons from four siblings; *st67* mutant, 2.53±0.64 wraps, *n*=15 axons from three mutants; *P*=0.01). Similarly to Schwann cells, we also noted swollen and elaborate endoplasmic reticulum in the cytoplasm of oligodendrocytes ([Fig. 3D,E](#f3-0060135){ref-type="fig"}).

![**Nodes of Ranvier are disrupted in the spinal cord of *st67* mutants and the spinal cord axons are hypomyelinated.** (A,B) Myelin basic protein (Mbp, red) and NaV (green) antibody staining in the ventral spinal cord at 3 dpf. No differences can be seen in the intensity of Mbp stain in *st67* mutants (B) compared with siblings (A), but NaV puncta (arrowheads) are greatly reduced in *st67* mutants (see also [Fig. 4](#f4-0060135){ref-type="fig"}). (C--E), TEM images showing cross-sections through the ventral spinal cord at 5 dpf. (C) At 5 dpf, many axons in sibling spinal cord are surrounded by several wraps of myelin (\*). (D) Fewer axons are myelinated (\*) in *st67* mutant spinal cord, and irregular oligodendrocyte cytoplasm was observed with visibly swollen ER (arrowheads) in all mutants examined. (E) Enlarged view of the boxed region in D. In D and E, arrowheads denote swollen ER. Sample sizes: 8 wild-type and heterozygous larvae and 3 mutant larvae. Scale bars: 20 μm (A,B); 1 μm (C,D).](DMM009217F3){#f3-0060135}

![***st67* disrupts zebrafish *sec63***. (A) Representation of Sec63 showing functional domains and the location of the lesion in the *st67* mutation. TM, transmembrane domain; DnaJ, DnaJ domain; Sec63, Sec63 domain; CC, coiled-coil region. Also shown are sequence traces from homozygous wild-type and *st67* mutant larvae. The *st67* mutation changes a conserved tyrosine to an aspartic acid in the Sec63 domain. A comparison of zebrafish and human Sec63 amino acid sequence in the vicinity of the *st67* mutation is also shown. The light blue box indicates the location of the lesion in *st67* zebrafish mutants. The asterisk marks the position of a *SEC63* mutation identified in human patients with PCLD (W651G) ([@b86-0060135]). (B--E) Representative images of antibody-stained preparations of the spinal cord of larvae of the indicated genotypes and injection treatments at 72 hpf. (B) Siblings injected with control solution show normal NaV clustering (arrowheads). (C) *st67* mutants injected with control solution show aberrant NaV clustering. (D,E) Siblings and *st67* mutants injected with 150 pg of synthetic *sec63* mRNA show normal NaV clustering. (F) Quantification of the total number of NaV puncta in two hemisegments (∼200 μm) of ventral spinal cord of sibling (black bars) and *st67* mutant larvae (gray bars) at 72 hpf following the indicated injection regimes. The *P* values for unpaired *t*-test comparisons (two-tailed) are shown; error bars indicate s.d. Sample sizes: 9 control-injected siblings. 6 control-injected mutants, 12 *sec63*-injected siblings and 11 *sec63*-injected mutants. Scale bar: 20 μm (B--E).](DMM009217F4){#f4-0060135}

*st67* disrupts zebrafish *sec63*
---------------------------------

By high-resolution genetic mapping, we determined that *st67* disrupts the zebrafish homolog of *sec63*. In *st67*, a T-to-G transversion is predicted to change a highly conserved tyrosine to an aspartic acid at amino acid position 647 ([Fig. 4A](#f4-0060135){ref-type="fig"}). All mutants tested were homozygous for the T-to-G mutation (*n*\>360), demonstrating that *sec63* is tightly linked to the *st67* mutation. To obtain additional evidence that *sec63* is disrupted by the *st67* mutation, we rescued the mutants by injecting synthetic mRNA encoding wild-type *sec63*. Injection of 150 pg of *sec63* mRNA into wild-type and heterozygous embryos did not affect the number or morphology of NaV clusters in the ventral spinal cord at 3 dpf ([Fig. 4D,F](#f4-0060135){ref-type="fig"}). *st67* mutants injected with control solution showed a significant reduction in the number of NaV clusters in the ventral spinal cord at 3 dpf compared with wild type ([Fig. 4C,F](#f4-0060135){ref-type="fig"}), whereas NaV clustering was rescued in mutants injected with 150 pg of wild-type *sec63* mRNA ([Fig. 4E,F](#f4-0060135){ref-type="fig"}). Together, these data indicate that *sec63* is disrupted by the *st67* mutation.

Sec63 is a member of the ER translocon machinery and is well conserved from yeast to human ([@b12-0060135]; [@b71-0060135]; [@b68-0060135]). Zebrafish Sec63 is 71% identical and 84% similar to human Sec63. Human Sec63 is predicted to span the ER membrane three times and contain a luminal N-terminus, a cytoplasmic C-terminus, with a coiled-coil region and a luminal DnaJ domain between the second and third transmembrane pass ([Fig. 4A](#f4-0060135){ref-type="fig"}) ([@b11-0060135]; [@b48-0060135]; [@b86-0060135]). RT-PCR showed that *sec63* is expressed at all stages examined in wild-type and *st67* mutants. ([supplementary material Fig. S3](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009217/-/DC1), data not shown), and whole-mount in situ hybridization showed that *sec63* is broadly expressed ([supplementary material Fig. S3B,C](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009217/-/DC1)) ([@b77-0060135]), with strong staining in the liver and pancreas ([supplementary material Fig. S3C](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009217/-/DC1)).

ER stress response is upregulated in *sec63^st67^* mutants
----------------------------------------------------------

To counter the accumulation of unfolded proteins in the ER lumen, genes encoding chaperone proteins are transcriptionally activated during the unfolded protein response (UPR), increasing the protein folding capacity of the ER. One of the best-characterized ER chaperones upregulated by the UPR is *BiP*, which encodes the immunoglobulin heavy-chain-binding protein ([@b35-0060135]), a chaperone that belongs to the highly conserved hsp70 protein family ([@b49-0060135]; [@b51-0060135]). If ER stress cannot be resolved, the UPR leads to transcriptional upregulation of pro-apoptotic genes, such as *CHOP* (C/EBP-homologous protein), which is downstream of the PERK-eIF2α pathway ([@b25-0060135]). ER transmembrane proteins including inositol-requiring protein 1 (IRE1), a kinase that possesses site-specific endoribonuclease (RNase) activity, also control UPR signaling. The only known target of this RNase activity is X-box binding protein 1 (XBP1). Upon accumulation of misfolded proteins in the ER lumen, IRE1 splices the mRNA of XBP1, excising a 26-nucleotide fragment. The generation of this noncanonically spliced mRNA is specific to UPR activation, and the translated protein is a potent activator of UPR target genes ([@b93-0060135]; [@b5-0060135]).

To test the hypothesis that the *sec63^st67^* mutation activates the UPR, we examined *xbp-1* splicing as well as *bip* and *chop* expression levels in *sec63^st67^* mutants. The UPR-specific spliced form of *xbp-1* was upregulated in *sec63^st67^* embryos and larvae at all time points examined ([Fig. 5A](#f5-0060135){ref-type="fig"}). Using quantitative real-time PCR (qRT-PCR), we also found that *bip* was upregulated in *sec63^st67^* mutants at 3 dpf and 5 dpf, and that *chop* is upregulated in *sec63^st67^* mutants at 5 dpf ([Fig. 5B,C](#f5-0060135){ref-type="fig"}). Together, these data show an upregulation of multiple UPR markers in *sec63^st67^* mutants, suggesting that ER stress levels are elevated, as one might expect in mutants with disruptions in *sec63*.

![**Markers of ER stress are elevated in *sec63^st67^* mutants.** (A) RT-PCR showing expression of spliced and unspliced *xbp-1* in individual larvae of the indicated genotypes and developmental stages. During the UPR, a 26-nucleotide fragment of *xbp-1* mRNA is spliced. RT-PCR shows that the spliced form of *xbp-1* (S) is enriched in *sec63^st67^* mutants compared with wild-type (WT) and *st67*/+ larvae. Unspliced *xbp-1* (US) is present in all samples. As a positive control for the assay, wild-type larvae treated with the ER stressor tunicamycin show upregulation of the spliced form of *xbp-1*. (B,C) qRT-PCR showing relative expression of UPR markers *bip* (B) and *chop* (C) in wild-type and heterozygous siblings (WT) vs *sec63^st67^* mutant larvae (*st67*) at the indicated stages. Error bars indicate s.d.](DMM009217F5){#f5-0060135}

*sec63^st67^* mutant livers develop abnormally
----------------------------------------------

Mutations in *SEC63* cause PCLD in humans, an inherited, progressive disorder characterized by the presence of numerous cysts throughout the liver ([@b19-0060135]). Although disease symptoms appear in adulthood, the cysts are thought to arise during embryonic development from intralobular bile ducts ([@b13-0060135], [@b59-0060135]). Interestingly, one of the disease-causing mutations in patients with PCLD affects a tryptophan residue near the *st67* lesion ([Fig. 4A](#f4-0060135){ref-type="fig"}) ([@b86-0060135]). To determine whether the *sec63^st67^* mutation causes liver pathology in zebrafish larvae, we examined the ultrastructure of this organ at 5 dpf and at 8 dpf. As in glia, at 5 dpf, we observed swelling and fragmenting of the ER, again indicative of ER stress ([supplementary material Fig. S4](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009217/-/DC1)). At 8 dpf, the changes were even more obvious: fragmentation and swelling of the ER with accumulation of a dense matrix in the ER lumen ([Fig. 6A,B](#f6-0060135){ref-type="fig"}) were accompanied by regions of empty cytoplasm ([Fig. 6C,D](#f6-0060135){ref-type="fig"}), smaller mitochondria with a dense matrix and wider cristae ([Fig. 6](#f6-0060135){ref-type="fig"}; [supplementary material Fig. S2](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009217/-/DC1)), as well as disrupted and disorganized bile canaliculi ([Fig. 6D](#f6-0060135){ref-type="fig"}). Finally, we observed multiple regions of *sec63^st67^* mutant livers laden with large lysosomes filled with debris and these were more frequent and prominent at 8 dpf than at 5 dpf ([Fig. 6F](#f6-0060135){ref-type="fig"}). This phenotype was also observed in the intestine of the mutants (data not shown), but never in wild-type siblings.

![***sec63^st67^* mutants develop numerous liver pathologies.** (A--F) TEM images showing liver ultrastructure at 8 dpf in wild-type and *sec63^st67^* mutant zebrafish. (A) Wild-type liver; arrow points to ER with normal morphology. (B) *sec63^st67^* mutant liver; ER is swollen (arrows) and cytoplasm is disrupted. (C,D) Ultrastructure of bile canaliculi (\*) in wild-type (C) and *sec63^st67^* mutant (D) livers. *sec63^st67^* bile canaliculi appear disorganized compared with the wild type. Lysosomes are filled with debris in *sec63^st67^* mutants (F; arrows) but not in the wild type (E). Scale bars: 500 nm (A--D); 2 μm (E,F).](DMM009217F6){#f6-0060135}

Additionally, ER stress has been linked to fatty liver disease in humans ([@b2-0060135]; [@b27-0060135]) and to steatosis liver pathologies in zebrafish ([@b6-0060135]). Therefore, to assess steatosis in *sec63^st67^* mutant livers, we performed Oil Red O staining at 3, 5 and 8 dpf. No changes in stain intensity were observed in *sec63^st67^* mutants at 3 dpf (data not shown; sample sizes were 11 wild type, 22 heterozygotes and 8 *sec63^st67^* mutants) or at 5 dpf ([Fig. 7](#f7-0060135){ref-type="fig"}; sample sizes were 6 wild type, 12 heterozygotes and 7 *sec63^st67^* mutants). However, at 8 dpf, all *sec63^st67^* mutant livers examined showed strong Oil Red O stain compared with wild-type and heterozygous siblings ([Fig. 7](#f7-0060135){ref-type="fig"}; sample sizes were 14 wild type, 34 heterozygous and 8 *sec63^st67^* mutants), which is indicative of liver steatosis. Together, our analyses show that the *sec63^st67^* mutation disrupts liver development in addition to myelinating glia in the PNS and CNS.

![***sec63^st67^* mutants develop liver steatosis.** (A--F′) Lateral views of larvae stained with Oil Red O of the indicated genotypes and at the indicated developmental stages. (A--C) Arrows indicate the location of the liver in 5 dpf larvae. *sec63^st67^* mutant livers (C, *n*=7) are indistinguishable from wild-type (A, *n*=6) or heterozygous (B, *n*=12) livers. (D--F) Boxed regions denote the areas enlarged in D′--F′. (D′--F′) Outlines denote the liver in 8 dpf larvae. *sec63^st67^* mutant livers (F,F′, *n*=8) show stronger Oil Red O stain than wild-type (D,D′, *n*=14) or heterozygous (E,E′, *n*=34) livers. Scale bars: 200 μm.](DMM009217F7){#f7-0060135}

DISCUSSION
==========

Starting with a genetic screen for mutants with abnormal nodes of Ranvier, we identified a mutation in *sec63* that disrupts nodal NaV clusters in the PNS and the CNS of zebrafish larvae. The specific disruption of myelination and liver development in *sec63^st67^* mutants is consistent with the requirements of myelinating glia and hepatocytes to synthesize very large amounts of membrane and secreted proteins during development, making these cells especially sensitive to perturbations of the secretory pathway ([@b91-0060135]; [@b65-0060135]; [@b73-0060135]; [@b1-0060135]; [@b52-0060135]; [@b8-0060135]). We show that multiple markers of the unfolded protein response are upregulated in *sec63^st67^* mutants and hypothesize that the pathologies we observe in myelinating glia (fragmented and swollen ER, disrupted NaV clustering and hypomyelination) are a general consequence of ER stress and disruption of the secretory pathway and not a specific function of Sec63 in node of Ranvier formation or myelination. Similarly, the liver steatosis and the pathologies we observed in hepatocytes (fragmented and swollen ER, smaller mitochondria with denser matrices and wider cristae, disrupted bile canaliculi and debris-laden lysosome accumulation) could also be caused by general ER stress in addition to disrupted protein trafficking. In this model, other cells with very active secretory pathways should be preferentially affected by the *sec63^st67^* mutation. Indeed, we also observed debris-laden lysosome accumulation in the mutant intestine (data not shown).

Comparison with previous analyses of Sec63 in yeast and mammals suggests a number of ways in which the missense mutation in the cytosolic region of Sec63 observed in *sec63^st67^* mutants could disrupt translocon function and protein folding. In yeast and mammals, the cytosolic region of Sec63 interacts with Sec62 ([@b53-0060135]; [@b81-0060135]; [@b90-0060135]; [@b89-0060135]; [@b87-0060135]); in yeast, this interaction is essential for protein transport into the ER and is thought to play the same role in higher vertebrates ([@b48-0060135]). In this way, the *sec63^st67^* mutation could lead to decreased preprotein translocation into the ER. The lumenal J-domain of Sec63 is required for interactions with the chaperone BiP ([@b4-0060135]; [@b69-0060135]; [@b43-0060135]; [@b7-0060135]; [@b81-0060135]). Although the *sec63^st67^* mutation is located in the cytosolic region, the lesion might also lead to a change in Sec63 structure or function that disrupts BiP interactions and therefore protein folding in the lumen of the ER. Finally, in yeast, the Sec61p-Sec63p-BiP translocation complex can also retrogradely affect transport of misfolded proteins out of the ER for cytosolic proteasome degradation ([@b57-0060135]). This function of the complex remains to be described in higher eukaryotes but if it is conserved, the *sec63^st67^* mutation might also inhibit transport and degradation of misfolded proteins. In each of these scenarios, a combination of UPR activation and reduced secretion of essential proteins might underlie the pathologies in *sec63^st67^* mutants.

Given the essential function of Sec63 in the secretory pathway, it is perhaps surprising that the *sec63^st67^* mutants survive for approximately 14 days. Indeed, germline deletion of *Sec63* in mammals results in fully penetrant early embryonic lethality ([@b20-0060135]). In zebrafish, maternally supplied transcripts or compensation by another translocon protein, ERj1, might account for the absence of the early, general defects observed in the *sec63^st67^* mutants. ERj1 is an Hsp40 family member related to Sec63 that also provides a luminal J-domain for BiP interactions. Importantly, expression of human ERj1 in yeast can complement mutations in *sec63p* ([@b34-0060135]). Another, not mutually exclusive, possibility is that the mutant protein encoded by the *sec63^st67^* allele retains enough activity to support some essential functions of the Sec63 protein.

The unfolded protein response in myelinating disorders
------------------------------------------------------

After UPR was first described in *Saccharomyces cerevisiae* ([@b33-0060135]; [@b55-0060135]), a growing body of evidence has implicated this evolutionarily conserved pathway as a causative factor in many human diseases including liver disease, renal disease, diabetes, cancer, neurodegenerative disease, heart disease and myelin disorders ([@b30-0060135]; [@b64-0060135]; [@b3-0060135]; [@b10-0060135]; [@b37-0060135]). The biogenesis of myelin requires the synthesis of extremely large amounts of myelin lipids and proteins ([@b91-0060135]; [@b65-0060135]; [@b73-0060135]; [@b1-0060135]). Accordingly, the UPR has been implicated in the pathogenesis of myelin disorders, including Pelizaeus-Merzbacher disease (PMD), vanishing white matter disease, multiple sclerosis and peripheral neuropathies ([@b82-0060135]; [@b38-0060135]; [@b39-0060135]; [@b45-0060135]; [@b92-0060135]; [@b56-0060135]).

In PMD, for example, several studies have shown that the mutant forms of the structural myelin protein proteolipid protein (PLP) and its alternatively spliced isoform DM20 accumulate in the ER of oligodendrocytes. This activates the UPR and leads to oligodendrocyte death ([@b24-0060135]; [@b23-0060135]; [@b72-0060135]; [@b74-0060135]; [@b14-0060135]; [@b15-0060135]). Although, a priori, one might postulate that the pathology in PMD results from reduced levels of PLP in the myelin, a phenotypic comparison of different *Plp* mutant alleles provides strong evidence against this possibility. Point mutations that cause accumulation of mutant PLP in the ER cause more severe phenotypes than null mutants that lack PLP entirely ([@b26-0060135]; [@b32-0060135]; [@b74-0060135]). Interestingly, although upregulation of CHOP during the UPR leads to apoptosis in most cell types ([@b64-0060135]), it appears to be protective in oligodendrocytes. Analysis of double mutant *CHOP* null;*PLP* mutant mice showed that the absence of *CHOP* exacerbated the clinical phenotype of *PLP* mutant mice ([@b72-0060135]). The mechanisms of the protective effect of CHOP on oligodendrocytes are not known, but these genetic studies emphasize the connection between UPR and diseases of the myelin. Furthermore, there is substantial evidence from numerous studies that the UPR plays a role in other myelin disorders affecting oligodendrocytes and Schwann cells (reviewed by [@b10-0060135]; [@b37-0060135]).

Sec63 in polycystic liver disease
---------------------------------

A number of mutations in *SEC63* have been identified in patients with autosomal dominant PCLD ([@b86-0060135]). PCLD is a progressive disorder characterized by many (\>20/liver) fluid-filled liver cysts that might or might not co-occur with autosomal dominant PCKD ([@b79-0060135]). PCKD is caused by mutations in *PKD1* and *PKD2*, which respectively encode polycystin-1 and polycystin-2 ([@b76-0060135]; [@b46-0060135]). PCLD without PCKD is caused by mutations in *SEC63* ([@b11-0060135]) or *PRKCSH* ([@b16-0060135]; [@b36-0060135]). Although polycystic livers retain normal function, cysts lead to increased liver volume, which causes significant morbidity as the enlarged liver impinges upon other organs and impairs their functions. Currently, there are no therapeutic interventions for PCLD and invasive surgery to remove or aspirate cysts or liver transplant represent the only treatment options ([@b18-0060135]; [@b28-0060135]). *SEC63* mutations in PCLD patients include a T-to-G missense mutation that changes a conserved tryptophan to a glycine at amino acid position 651 ([@b86-0060135]). This mutation is located in the same cytosolic region of Sec63 as the *st67* mutation ([Fig. 4A](#f4-0060135){ref-type="fig"}). This region of Sec63 is located between two β-sheets; in humans, the W651G mutation is predicted to profoundly alter the structure and therefore function of Sec63 ([@b86-0060135]).

PCLD can also be caused by mutations in *PRKCSH* ([@b16-0060135]; [@b36-0060135]), which encodes the β-subunit of glucosidase II (protein kinase C substrate 80K-H, also called hepatocystin), an enzyme involved in the oligosaccharide processing of newly synthesized glycoproteins ([@b17-0060135]). PCLD patients are heterozygous for mutations in *PRKCSH* or *SEC63*, and loss of *PRKSCH* heterozygosity has been observed in cells obtained from liver cyst biopsies ([@b29-0060135]). Loss of heterozygosity (LOH) for *SEC63* mutations remains to be described, but given the observed LOH in *PRKSCH* mutations, a similar model has been proposed for *SEC63* ([@b94-0060135]). In line with this model, a recent report in mouse shows that tissue-specific homozygous loss-of-function mutations in *Sec63* result in kidney and liver cyst formation ([@b20-0060135]). In addition, our analysis shows that homozygous *sec63^st67^* mutants develop liver pathology. We noted multiple abnormalities in hepatocytes of *sec63^st67^* mutants, although we did not observe cysts in mutant livers or kidneys. Although human PCLD cysts are thought to arise in bile ducts, our observations of pathology in hepatocytes are consistent with a previous report that shows robust expression of Sec63 in human fetal hepatocytes ([@b85-0060135]). It is possible that the pathologies that we observed in hepatocytes precede cyst formation in bile ducts, and that cysts might become evident at later stages than we were able to analyze.

It is unclear how mutations in *SEC63* lead to PCLD in humans, but there are at least three possible, non-mutually exclusive models. One possibility is that reduced expression of a protein(s) trafficked through the ER causes overgrowth and cyst formation in the liver. In accordance with this model, a recent study provided evidence that levels of polycystin-1 protein are reduced in *Sec63* mutant mouse cells and suggested that this is a key contributing factor in cyst formation ([@b20-0060135]). A second possibility is that Sec63 binds to and retains specific proteins at the cytosolic face of the ER, so that Sec63 mutations mislocalize these proteins. This model is supported by the finding that Sec63 physically interacts with the cytosolic protein nucleoredoxin ([@b48-0060135]), which interacts with Dishevelled to negatively regulate the Wnt--β-cateninin and Wnt--planar cell polarity signaling pathways ([@b21-0060135]; [@b22-0060135]). Despite this possible connection to Wnt signaling, we did not observe defects in the expression of Wnt targets *axin2* and *naked1* in *sec63^st67^* mutants at 24 hpf (data not shown). Our results highlight a third possible contributing factor: ER stress.

It is likely that a combination of these factors contributes to the final disease outcome. For example, Fedeles et al. reported that treatment with a proteasome inhibitor ameliorated kidney cyst pathology in mouse models of PCKD ([@b20-0060135]). The authors proposed a model in which this treatment raised the levels of polycystin-1 and also killed cells under severe ER stress. Future work will define the relationship between UPR, the trafficking of specific proteins such as polycystin-1, and cyst formation. We expect that the *sec63^st67^* mutant zebrafish described in this study will prove useful in future efforts to dissect the pathogenesis of PCLD as well as the consequences of UPR induction in myelinating glia. Future chemical modifier screens might uncover small molecules that alter liver and myelin phenotypes in *sec63^st67^* mutants and perturbation of ER stress or unbiased screens in heterozygous larvae and adults could shed light on the pathways that drive pathologic alterations in liver, myelinated axons and other organs.

METHODS
=======

Fish strains
------------

Zebrafish embryos were raised at 28.5°C and staged according to published methods ([@b31-0060135]). *N*-ethyl-*N*-nitrosourea (ENU) mutagenesis and rearing of fish for screening were performed as described ([@b58-0060135]).

Genetic mapping and positional cloning of *sec63^st67^*
-------------------------------------------------------

Wild-type and *st67* mutants at 5 dpf were sorted by their NaV-clustering phenotype. The *st67* mutation was genetically localized via bulked segregant analysis with PCR-based simple sequence length polymorphisms (SSLPs) by standard methods ([@b75-0060135]). Fully sequenced BACs within the *st67* interval were identified from the zebrafish fpc database (<http://www.sanger.ac.uk/Projects/D_rerio/WebFPC/zebrafish>) and the Ensembl genome browser (<http://useast.ensembl.org/Danio_rerio/Info/Index>). Predicted coding regions in these BAC sequences were used in additional mapping experiments to further refine the *st67* interval. These experiments placed the *st67* mutation in a region of LG20 between the clones CH211-278N15 (GenBank accession \#BX927123.8) and CH211-260K9 (GenBank accession \#BX649264.4). We sequenced the coding regions of the genes in the interval to find the lesion in *sec63*.

Genotyping
----------

To genotype individual larvae in the phenotypic analyses, the *st67* mutation was scored in genomic DNA samples via a TaqαI restriction enzyme recognition site introduced by the lesion. We used the following primers to amplify fragments from genomic DNA templates: 5′-GGTCACTCTGTCATCGGTTCT-3′ and 5′-TGTGTGATGCTCATGTTTTGC-3′. To genotype individual larvae in the qRT-PCR analysis (see below), the *st67* mutation was again scored via TaqαI cleavage. We used the following primers to amplify cDNA generated from single larvae: 5′-ACAAAGGCAGCGAATCAGAC-3′ and 5′-TGGAGCAGGGAATTTCAGTT-3′. The PCR products were digested with TaqαI to generate a smaller fragment from the mutant allele.

In situ hybridization and fluorescent antibody labeling
-------------------------------------------------------

In situ hybridization was performed with standard protocols ([@b78-0060135]). To synthesize the *sec63* riboprobe, we used the following primers to amplify an 886 bp fragment from a full-length zebrafish *sec63* cDNA (GenBank accession \#BC076198) obtained from Open Biosystems: 5′-TAAAGGCGGAGATGAGGCTA-3′, 5′-CTTCTCCTCCCCCAGAAATC-3′. The PCR product cloned into pCR II-TOPO vector (Invitrogen) and sequenced. This construct was linearized with *Not*I and transcribed with SP6 for antisense and linearized with *Bam*HI and transcribed with T7 for sense. Antibody labeling and image acquisition was performed as described for anti-panNaV, anti-acetylated tubulin, and anti-Mbp ([@b83-0060135]; [@b84-0060135]; [@b47-0060135]). For NaV cluster quantification in the PNS, we counted the total number of NaV clusters labeled by the anti-panNaV antibody along the entire length of the posterior lateral line nerve. For NaV cluster quantification in the CNS, we counted the number of NaV clusters labeled by the anti-panNaV antibody in two hemisegments (∼200 μm) of ventral spinal cord. Genotypes were determined by PCR assay after image acquisition (immunohistochemistry) or from larval tail clips after in situ hybridization.

Microinjections
---------------

Full-length zebrafish *sec63* cDNA (GenBank accession \#BC076198) was obtained from Open Biosystems and subcloned into the pCS2+ expression vector. The sequence was confirmed, and synthetic mRNA encoding *sec63* was generated with the SP6 mMessage mMachine kit (Ambion) after linearization with *Apa*I. For the rescue experiments, embryos were injected at the 1--2 cell stage with 150 pg of *sec63* mRNA in 1.5 nl of 1× Danieau buffer with 5 mg/ml Phenol Red. Control embryos were injected with 1.5 nl of 1× Danieau buffer with 5 mg/ml Phenol Red.

Oil Red O stain
---------------

Oil Red O staining was performed as described ([@b54-0060135]). Genotypes were determined by PCR from larval tail clips following Oil Red O staining.

RT-PCR
------

For traditional RT-PCR, total RNA was isolated from pooled wild-type embryos and larvae at the stages indicated in [supplementary material Fig. S3](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009217/-/DC1) using TRIZOL according to standard protocols. cDNA was reverse transcribed using SuperScript II reverse transcriptase and random hexamers according to the manufacturer's instructions. To control for genomic DNA contamination, reverse transcriptase was omitted using the same RNA samples. For RT-PCR, we used the following primers: *sec63*, 5′-GATTTCTGGGGGAGGAGAAG-3′ and 5′-TCCCTCTGCTTCGTCTGATT-3′ (457 bp); *xbp-1*, 5′-CTGTTGCGAGACAAGACGAG-3′ and 5′-GAAGAGCTCGGAGTCAAGGA-3′ (310 bp unspliced, 275 bp spliced). Either *ef1a* ([@b47-0060135]) or *gapdh*: 5′-TGACCCATTCATTGACCTTG-3′ and 5′-GCATGACCATCAATGACCAG-3′ (117 bp) were used as normalization standards. As an additional control for genomic DNA contamination, all primer pairs spanned introns. RT-PCR was performed according to standard protocols and cycling conditions.

qRT-PCR
-------

For qRT-PCR, total RNA was isolated from individual larvae obtained from a *sec63^st67^*/+ intercross at 1, 3 and 5 dpf using the RNeasy Micro Kit (Qiagen) according to the manufacturer's instructions. cDNA was reverse transcribed using SuperScript II reverse transcriptase and oligo(dT) primers according to the manufacturer's instructions. To control for genomic DNA contamination, reverse transcriptase was omitted using the same RNA samples. For qRT-PCR, we used the following primers: *bip*, 5′-TCAGCGTCAGGCCACTAA-3′ and 5′-GTCAGCAGAGACACGTCAAA-3′ (171 bp); *chop*, 5′-CGGTTCCCGACACATCA-3′ and 5′-CACTTTCCTTTCATTCTCCTGTT-3′ (179 bp). *gapdh* was used as a normalization standard with the primers listed in RT-PCR. As an additional control for genomic DNA contamination, all primer pairs spanned introns. qRT-PCR was performed using SYBR Green Master Mix (Applied Biosystems) and a Roche LightCycler 2.0 according to the manufacturers' instructions. Fold change was calculated using the 2^−ΔΔCt^ method ([@b40-0060135]).

Tunicamycin administration
--------------------------

Tunicamycin (2.5 μg/ml; Sigma) or an equal volume of DMSO was added to the embryo medium of manually dechorionated embryos from 3 dpf to 5 dpf. These embryos were used as a positive control for the ER stress assays ([Fig. 5](#f5-0060135){ref-type="fig"} and data not shown).

Transmission electron microscopy
--------------------------------

Larval fixation and embedding for electron microscopy was performed as described ([@b9-0060135]). The number of larvae examined in each experiment are given in the figure legends. Sections were acquired and stained as described ([@b9-0060135]), and imaged on a Jeol 1230 or a Philips 410 electron microscope.
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